A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment

The prognosis of advanced stage neuroblastoma patients remains poor and, despite intensive therapy, the 5-year survival rate remains less than 50%. We previously identified histone deacetylase (HDAC) 8 as an indicator of poor clinical outcome and a selective drug target for differentiation therapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jing, Najafi, Sara, Stäble, Sina, Fabian, Johannes, Koeneke, Emily, Kolbinger, Fiona R., Wrobel, Jagoda K., Meder, Benjamin, Distel, Martin, Heimburg, Tino, Sippl, Wolfgang, Jung, Manfred, Peterziel, Heike, Kranz, Dominique, Boutros, Michael, Westermann, Frank, Witt, Olaf, Oehme, Ina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261943/
https://www.ncbi.nlm.nih.gov/pubmed/29515255
http://dx.doi.org/10.1038/s41418-018-0080-0

Ejemplares similares

Ejemplares similares